[company_age]unknown[/company_age][employees]2-10 employees[/employees][funding]Seed[/funding][description]GenoME Diagnostics is a spin-out company from Queen's University Belfast, specializing in developing a novel blood test for earlier and more accurate diagnosis of ovarian cancer. Their lead product, OvaME, utilizes droplet digital PCR technology to detect DNA methylation changes in a minimal blood volume, offering higher sensitivity and precision compared to traditional PCR methods. GenoME Diagnostics aims to improve upon the current CA125 test, which suffers from inaccuracies and limited sensitivity in early-stage ovarian cancer detection. Their technology platform has the potential to be applied to biomarker discovery and development in a wide range of diseases and applications, both internally and through partnerships.[/description][ps]OvaME - Blood test for earlier and more accurate diagnosis of ovarian cancer.[/ps]